Market capitalization | NOK3.27b |
Enterprise Value | NOK3.11b |
P/E (TTM) P/E ratio | 31.48 |
EV/Sales (TTM) EV/Sales | 5.54 |
P/S ratio (TTM) P/S ratio | 5.81 |
P/B ratio (TTM) P/B ratio | 8.07 |
Dividend yield | 2.52% |
Last dividend (FY23) | NOK4.50 |
Revenue growth (TTM) Revenue growth | 6.88% |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
1 Analyst has issued a forecast Medistim:
1 Analyst has issued a forecast Medistim:
Dec '24 |
+/-
%
|
||
Revenue | 563 563 |
7%
7%
|
|
Gross Profit | 239 239 |
5%
5%
|
|
EBITDA | 156 156 |
0%
0%
|
EBIT (Operating Income) EBIT | 131 131 |
0%
0%
|
Net Profit | 104 104 |
0%
0%
|
In millions NOK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medistim ASA engages in the development, manufacturing, and distribution of medical equipment and consumables. It operates through the following segments: Lease of Equipment, Capital Sales/Consumables, and Third Party Products. The Lease of Equipment segment delivers system and probes at the customer site free of charge. The Capital Sales/Consumables segment consists of probe sales, lease, and PPP cards. The Third Party Products segment offers products related with surgery. Its products include MiraQ Cardiac, MiraQ Vascular, MiraQ Ultimate, Imaging Probe, and Flow Probe. The company was founded by Kari Mette Tjolsen Pah on June 10, 1984 and is headquartered in Oslo, Norway.
Head office | Norway |
CEO | Kari Krogstad |
Founded | 1984 |
Website | www.medistim.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.